Salim Syed
Stock Analyst at Mizuho
(1.92)
# 3,072
Out of 4,893 analysts
81
Total ratings
36.92%
Success rate
-8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.80 | +677.78% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $36.59 | +129.57% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $135.33 | +24.88% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $300.37 | -6.78% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $114.54 | +2.15% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $7.95 | +176.73% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $36.26 | +349.53% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $9.54 | +88.78% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $22.75 | +49.45% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $59.00 | +67.80% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $46.27 | +14.55% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.10 | +5,840.59% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $0.87 | +2,321.59% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $18.35 | +96.19% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.80
Upside: +677.78%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $36.59
Upside: +129.57%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $135.33
Upside: +24.88%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $300.37
Upside: -6.78%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $114.54
Upside: +2.15%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $7.95
Upside: +176.73%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $36.26
Upside: +349.53%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $9.54
Upside: +88.78%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.75
Upside: +49.45%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $59.00
Upside: +67.80%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $46.27
Upside: +14.55%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $0.10
Upside: +5,840.59%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $0.87
Upside: +2,321.59%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $18.35
Upside: +96.19%